Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from April 2021.
Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from April 2021.
5. Caring for the Geriatric Patient: What Oncology Nurses Need to Know
The cover story of our latest issue examines why oncology nurses must consider many factors when treating geriatric patients, from drug-drug interactions to treatment education and functional age.
4. Lurbinectedin Shows Promise in Small Cell Lung Cancer Treatment
Wade T. Iams, MD, discusses the efficacy and safety of lurbinectdin in in patients with small cell lung cancer, the impact of its approval on the paradigm, and remaining questions regarding its use.
3. Breast Cancer Surgery in a Pandemic: What's the Best Approach?
In a recent interview, breast surgeon Cindy Matsen, MD, discusses the best practices for breast cancer surgery during the COVID-19 pandemic.
2. FDA Authorizes Marketing for AI Colon Cancer Detection Device
Earlier this month, the FDA authorized the marketing of the first device that utilizes artificial intelligence based on machine learning to help clinicians detect lesions like polyps or suspected tumors in the colon in real time during a colonoscopy.
1. Approach Health Disparities From All Angles
In honor of National Minority Health Month, this feature highlights the need for health care and community sectors to come together and improve cancer outcomes for underserved populations.
Thanks for reading!
FDA Approves T-DXd for Previously Treated HER2-Low and -Ultralow Metastatic Breast Cancer
Published: January 27th 2025 | Updated: January 28th 2025T-DXd has received FDA approval for the treatment of unresectable or metastatic HR+, HER2-low/-ultralow breast cancer in patients whose disease progressed on prior endocrine therapy in the metastatic setting.
ctDNA Status May Be Prognostic for DFS With Celecoxib for Stage III Resected Colon Cancer
January 26th 2025While ctDNA positivity was linked to worse overall disease-free survival (DFS) in stage III resected colon cancer, it was associated with significantly improved DFS with celecoxib compared to placebo.